Not an actual patient with Fabry disease.
Learn about a no-charge option for genetic testing to help you confirm a diagnosis and determine your patient’s specific GLA variant.
AMICUS ASSIST is a program designed to provide assistance and support to help eligible patients with Fabry disease and an amenable GLA variant obtain access to Galafold.*
*Patients must be prescribed Galafold for an approved indication to be eligible for support from AMICUS ASSIST.
Understand more about the complexities of this disease, including signs, symptoms, how diagnosis can vary between genders, and much more.
Sponsored, no-charge genetic testing and counseling for patients suspected of having a lysosomal storage disease (LSD) and patients suspected of having a familial cardiomyopathy or arrhythmia.*
Click here to learn more.
While third parties and commercial organizations may provide financial support for this program, tests and services are performed by Invitae. Healthcare professionals must confirm that patients meet certain criteria to use the program. Third parties and commercial organizations may receive de-identified patient data from this program, but at no time would they receive patient identifiable information. Third parties and commercial organizations may receive contact information for healthcare professionals who use this program. Genetic testing and counseling are available in the US and Canada. Healthcare professionals and patients who participate in this program have no obligation to recommend, purchase, order, prescribe, promote, administer, use, or support any other products or services from Invitae or from third parties or commercial organizations.
Detect lysosomal storage diseases (LSDs)
The Invitae Detect LSDs program offers sponsored, no-charge genetic testing and counseling to diagnose LSDs, bringing patients closer to an accurate diagnosis and appropriate clinical management. To order a test, please visit www.invitae.com/detectLSDs.
Detect a familial cardiomyopathy or arrhythmia
The Invitae Detect Cardiomyopathy and Arrhythmia program offers no-charge genetic testing and counseling for people suspected of having a familial cardiomyopathy or arrhythmia. To order a test, please visit www.invitae.com/detect-cardiomyopathy-arrhythmia.
Additional details about the program, as well as terms and conditions, are available for you and your patients at www.invitae.com.
This form serves a dual purpose: as a prescription for Galafold and as a way for patients to register for AMICUS ASSIST.
Learn more about Galafold and its volume of distribution.
Help your patients establish a dosing regimen with Galafold by using the Galafold® MyDay app. Download this postcard to have on hand to give to your Galafold patients.
This flashcard has key, quick-hitting information about Galafold, dosing and administration, and patient support.
Discover more about the impact Fabry disease has on the kidneys and other organ systems, and how treatment with Galafold may help.
INDICATIONS AND USAGE
Galafold® (migalastat) is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data.
This indication is approved under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.